Study Evaluating the Safety and Efficacy of AR-15512 (COMET-3)

Aerie Pharmaceuticals

Status and phase: Completed; Phase 3

Conditions: Dry Eye Disease

Treatments: Drug: 0.003% AR-15512 ophthalmic solution; Drug: AR-15512 vehicle ophthalmic solution

Study type: Interventional

Funder types: Industry

Identifiers

NCT05360966

AR-15512-CS302

Details and patient eligibility

About

This will be a Phase 3, multicenter, vehicle-controlled, double-masked, randomized study conducted at approximately 20 sites in the United States. All subjects enrolled will have dry eye disease (DED). The study will consist of Screening (Day -14) and Baseline (Day 1) visits as well as visits at Day 7, Day 14, Day 28, and Day 90 (Study Exit) for an individual duration of participation of approximately 15 weeks.

Full description

At the end of the Screening Visit, all qualified subjects will be assigned to administer one drop of AR-15512 Vehicle twice a day to both eyes for approximately 14 days (vehicle run-in period). After the vehicle run-in period, subjects will be re-evaluated for signs and symptoms of Dry Eye Disease (DED). Subjects who requalify based on inclusion/exclusion criteria will be enrolled in the study and randomized in a 1:1 ratio to receive 0.003% AR-15512 or AR-15512 Vehicle administered as 1 drop in each eye twice a day for 90 days. At the end of the Day 90 visit, subjects will exit the study.

Aerie Pharmaceuticals was acquired by Alcon on November 22, 2022.

Enrollment: 467 patients

Sex: All

Ages: 30+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Key Inclusion Criteria:

• Signs and symptoms of dry eye disease (DED) at the Screening and Baseline visits;
• Corrected visual acuity of +0.70 logarithm Minimum angle of resolution (LogMAR) or better in both eyes at Screening and Baseline visits;
• Other protocol-specified inclusion criteria may apply.

Key Exclusion Criteria:

• History or presence of any ocular disorder or condition (other than DED) in either eye that would, in the opinion of the investigator, likely interfere with the interpretation of the study results or subject safety;
• Regular use of lid hygiene within 14 days prior to the Screening visit or any planned use during the study;
• Use of artificial tears within 2 hours prior to the Screening visit or anticipated use during the study;
• Medication use as specified in the protocol;
• History or presence of significant systemic disease;
• Other protocol-specified exclusion criteria may apply.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

467 participants in 2 patient groups, including a placebo group

0.003% AR-15512

Experimental group

Description:

0.003% AR-15512 ophthalmic solution, one drop in each eye twice a day for 90 days

Treatment:

Drug: 0.003% AR-15512 ophthalmic solution

AR-15512 Vehicle

Placebo Comparator group

Description:

AR-15512 vehicle ophthalmic solution, one drop in each eye twice a day for 90 days

Treatment:

Drug: AR-15512 vehicle ophthalmic solution